One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Incyte Corporation logo
Incyte Corporation INCY
$ 120.28 -1.19%
report update icon

Quarterly report 2026-Q3
added 10-29-2026

Incyte Corporation Income Statement 2025-2008 | INCY

Brief overview of income trends at Incyte Corporation

The figures are compared over a five-year interval. The revenue attributed to Incyte Corporation moved from 2.7 billion dollars to 5.1 billion dollars between the two endpoints. Overall revenue changed by +92.8%, equal to an annualized rate of about 14%. The company expanded its sales base at a healthy rate.

Gross profit changed from 2.5 billion dollars to 4.8 billion dollars (+88.1%). The relationship between sales and direct costs deteriorated. Comparing the endpoints gives gross margins of 95.1% and 92.8%. Weakening gross profitability reduces the quality of the top-line trend.

Over the period, EBITDA shifted from −212 million dollars to 1.6 billion dollars, a change of +859%. EBITDA grew faster than revenue, indicating positive operating leverage. At the operating-margin level, the figure shifted from −7.9% to 31.3%. A wider margin confirms stronger operating efficiency.

Net income moved from −296 million dollars at the start to 1.3 billion dollars at the end. The company restored profitability by the end of the period.

Market capitalization changed from $19.6 billion to $19.5 billion (−0.6%). The financial trend was stronger than the market valuation.

Conclusion

The figures do not all move in the same direction. The constructive conclusion rests on improving net profitability, a larger revenue base and positive operating leverage. The weaker side of the profile includes a lower gross margin. Further direction will depend on top-line growth, operating profitability, and net income.

Annual Income Statement Incyte Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

19.5 B 14.1 B 13.2 B 17.6 B 16.4 B 19.6 B 15.7 B 17 B 18.9 B 22.2 B 12.7 B 13.4 B 9.86 B 2.31 B 2.2 B 1.56 B 369 M -

Shares

195 M 207 M 224 M 222 M 220 M 218 M 215 M 212 M 205 M 188 M 180 M 168 M 148 M 130 M 125 M 123 M 103 M -

Historical Prices

99.7 67.9 59.2 79.2 74.3 89.8 73.1 80.6 90.3 121 70.6 79.7 65.5 18.4 17.7 12.6 3.58 9.03

Net Income

1.29 B 32.6 M 598 M 341 M 949 M -296 M 447 M 109 M -313 M 104 M 6.53 M -48.5 M -83.1 M -44.3 M -187 M -31.8 M -212 M -

Revenue

5.14 B 4.24 B 3.7 B 3.39 B 2.99 B 2.67 B 2.16 B 1.88 B 1.54 B 1.11 B 754 M 511 M 355 M 297 M 94.5 M 170 M 9.26 M -

Cost of Revenue

372 M 312 M 255 M 207 M 151 M 131 M 114 M 94.1 M 79.5 M 58.2 M - - - - - - - -

Gross Profit

4.77 B 3.93 B 3.44 B 3.19 B 2.84 B 2.54 B 2.04 B 1.79 B 1.46 B 1.05 B 727 M 508 M 354 M 297 M 94.5 M - - -

Operating Income

1.51 B 61.4 M 621 M 579 M 586 M -264 M 402 M 129 M -243 M 145 M 50.7 M -4.8 M -16.1 M 1.15 M -143 M 14 M -140 M -

Interest Expense

25.1 M 12.8 M 2.55 M 2.67 M 1.91 M 2.17 M 1.86 M 1.54 M 6.9 M 38.7 M 45.6 M 46.8 M 38.7 M 46.1 M 43.8 M 43.3 M 32.1 M -

EBITDA

1.61 B 151 M 703 M 647 M 644 M -212 M 476 M 210 M -184 M 221 M 57.7 M -1.45 M -14.8 M 1.91 M -116 M 38.5 M -123 M -

Operating Expenses

3.25 B 3.87 B 2.82 B 2.61 B 2.25 B 2.8 B 1.62 B 1.63 B 1.69 B 885 M 676 M 513 M 370 M 296 M 238 M -14 M - -

General and Administrative Expenses

1.38 B 1.24 B 1.16 B 1 B 740 M 517 M 469 M 434 M 366 M 303 M 197 M 166 M 110 M 85.4 M 58.2 M 32.3 M 27.6 M -

All numbers in USD currency

Quarterly Income Statement Incyte Corporation

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

203 M 200 M 199 M 745 K 196 M 194 M 194 M -4.65 M 193 M 218 M 224 M 200 M 224 M 223 M 223 M 203 M 222 M 222 M 221 M 185 M 221 M 220 M 220 M 219 M 219 M 220 M 217 M 216 M 215 M 215 M 214 M 213 M 213 M 212 M 212 M 211 M 207 M 205 M 195 M 189 M 188 M 188 M 187 M 186 M 181 M 179 M 172 M 170 M 169 M 168 M 165 M 162 M 155 M 142 M 134 M 132 M 131 M 129 M 127 M -250 M 126 M 125 M 123 M

Net Income

-785 M 586 M 303 M 299 M 424 M 405 M 158 M 201 M 106 M -445 M 170 M 201 M 171 M 204 M 21.7 M 28.5 M 113 M 161 M 38 M 564 M 182 M 149 M 53.5 M 150 M -15.2 M 149 M -721 M 111 M 128 M 105 M 102 M 69.1 M 29.2 M 52.4 M -41.1 M -150 M 36.1 M -12.5 M -187 M 8.87 M 36.9 M 34.4 M 24 M 55.2 M -39.6 M 9.29 M -18.4 M -36.9 M 59.3 M -36.9 M -34 M -42.9 M -22 M -2.57 M -15.7 M 18.8 M -21.7 M 4.04 M -45.4 M -55.1 M -53.1 M -51.9 M -26.5 M

Revenue

1.56 B 1.67 B 1.27 B 1.51 B 1.37 B 1.22 B 1.05 B 1.18 B 1.14 B 1.04 B 881 M 1.01 B 919 M 955 M 809 M 927 M 823 M 911 M 733 M 863 M 813 M 706 M 605 M 790 M 621 M 706 M 569 M 579 M 552 M 530 M 498 M 528 M 450 M 522 M 382 M 444 M 382 M 326 M 384 M 326 M 269 M 246 M 263 M 244 M 188 M 163 M 159 M 124 M 198 M 99.6 M 89.8 M 97.1 M 85.1 M 102 M 71.1 M 114 M 60.5 M 86.5 M 36.2 M 28.9 M 16.8 M 16.8 M 32 M

Cost of Revenue

109 M 105 M 105 M 121 M 99 M 78.8 M 73.2 M 88.5 M 86 M 76.6 M 61 M 69.8 M 60.1 M 68.3 M 56.8 M 59.2 M 54.6 M 50.6 M 42.6 M 43.9 M 39.9 M 38 M 29.2 M - 34.3 M 38 M 27.3 M 32.2 M 30 M 29.4 M 22.6 M 26.4 M 24.8 M 24.9 M 18.1 M 22.4 M 22 M 20.3 M 14.8 M - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

1.45 B 1.57 B 1.17 B 1.39 B 1.27 B 1.14 B 980 M 1.09 B 1.05 B 967 M 820 M 944 M 859 M 886 M 752 M 868 M 769 M 861 M 691 M 819 M 773 M - 575 M - - 668 M 541 M 547 M 522 M 501 M 475 M 502 M 425 M 497 M 364 M 422 M 359 M 306 M 369 M - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-708 M 698 M 301 M 336 M 444 M 530 M 205 M 302 M 146 M -478 M 91.9 M 187 M 215 M 194 M 24.8 M 70.1 M 138 M 254 M 117 M 111 M 235 M 141 M 98.8 M - 5.33 M 141 M -664 M 95 M 134 M 98.6 M 74.1 M 82 M 31.1 M 83.2 M -67.1 M -132 M 15 M 7.26 M -133 M 42.1 M 22.3 M 44.6 M 36 M 65.1 M -101 K -7.39 M -6.94 M -25.6 M 69.9 M -26.2 M -22.9 M -16.1 M -13.2 M 17.3 M -4.1 M 30.3 M -10.1 M 15.2 M -34.2 M -44.1 M -42.1 M -41.1 M -15.8 M

Interest Expense

1.17 M 6.28 M 2.77 M 5.66 M 4.04 M 7.31 M 8.1 M 1.61 M 4.93 M 8.29 M -2.03 M -108 M 46.4 M 42.7 M 32.9 M -13.8 M 11.5 M 522 K 1.26 M 5.72 M 1.95 M 358 K -1.41 M - 544 K 4.39 M 8.66 M 15.8 M 12 M 15 M 9.37 M 11.3 M 10.2 M 5.81 M 4.46 M 6.45 M 5.49 M 4.07 M 1.15 M 9.47 M 9.48 M 9.66 M 10.1 M 10.2 M 11.2 M 11.5 M 12.7 M 12.5 M 11.5 M 11.4 M 11.4 M 8.93 M 7.7 M 10.3 M 11.7 M 11.8 M 11.6 M 11.4 M 11.3 M 11.2 M 11 M 10.9 M 10.8 M

EBITDA

-708 M 724 M 325 M 293 M 468 M 553 M 228 M 259 M 169 M -456 M 114 M 149 M 236 M 214 M 44 M 42 M 155 M 271 M 133 M 111 M 278 M 141 M 113 M - 44 M 156 M -651 M 75.3 M 148 M 112 M 88 M 62.7 M 44.9 M 96.7 M -53.7 M -150 M 27 M 19.6 M -118 M 13.8 M 39.2 M 57.4 M 47.1 M 42.1 M 11.1 M 3.87 M 4.9 M -49.7 M 79.8 M -16.5 M -13.3 M -34.8 M -8.62 M 25.4 M 3.64 M 10.1 M -2.56 M 22.6 M -27 M -61.9 M -35.2 M -34.5 M -9.4 M

Operating Expenses

2.16 B 871 M 867 M 1.05 B 823 M 606 M 775 M 789 M 906 M 1.45 B 728 M 756 M 644 M 693 M 727 M 797 M 630 M 606 M 574 M 708 M 538 M - 477 M - - 527 M 1.21 B 452 M 387 M 402 M 401 M 420 M 394 M 413 M 431 M 554 M 344 M 299 M 503 M -42.1 M -22.3 M -44.6 M -36 M -65.1 M 101 K 7.39 M 6.94 M 25.6 M -69.9 M 26.2 M 22.9 M 16.1 M 13.2 M -17.3 M 4.1 M -30.3 M 10.1 M -15.2 M 34.2 M 44.1 M 42.1 M 41.1 M 15.8 M

General and Administrative Expenses

364 M 352 M 328 M 390 M 329 M 331 M 326 M 327 M 309 M 306 M 300 M 288 M 268 M 284 M 316 M 273 M 266 M 253 M 210 M 226 M 191 M 169 M 154 M - 121 M 169 M 111 M 136 M 103 M 106 M 124 M 108 M 96.5 M 108 M 121 M 97.7 M 91.3 M 90.1 M 87.2 M 96.1 M 75.8 M 66.8 M 64.6 M 52.5 M 47.6 M 51.7 M 44.9 M 48.5 M 39.4 M 40.9 M 37 M 38 M 26.4 M 23.2 M 22.3 M 23.7 M 20.5 M 19.7 M 21.4 M 21.2 M 14.3 M 11.9 M 10.8 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Incyte Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Annexon Annexon
ANNX
$ 4.2 -0.71 % $ 651 M usaUSA
AbbVie AbbVie
ABBV
$ 293.87 0.19 % $ 520 B usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 151.6 -3.2 % $ 19.9 B usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 302.6 -0.19 % $ 23.6 B usaUSA
Theratechnologies Theratechnologies
THTX
- - $ 83.9 M canadaCanada
Liquidia Corporation Liquidia Corporation
LQDA
$ 51.37 7.31 % $ 4.42 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 45.05 -9.97 % $ 4.05 B schweizSchweiz
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
$ 48.48 -5.96 % $ 5.56 B usaUSA
Geron Corporation Geron Corporation
GERN
$ 0.96 -3.71 % $ 640 M usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 62.8 1.06 % $ 128 B usaUSA
Titan Pharmaceuticals Titan Pharmaceuticals
TTNP
- -3.76 % $ 3.47 M usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
$ 7.4 -0.13 % $ 113 M australiaAustralia
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 30.68 -1.81 % $ 2.04 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.0 -6.76 % $ 48.8 M israelIsrael
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
$ 317.26 0.99 % $ 6.14 B usaUSA
Eli Lilly and Company Eli Lilly and Company
LLY
$ 1 432.7 1.47 % $ 1.29 T usaUSA
TCR2 Therapeutics TCR2 Therapeutics
TCRR
- - $ 58.1 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
TFF Pharmaceuticals TFF Pharmaceuticals
TFFP
- -60.05 % $ 125 K usaUSA
Mesoblast Limited Mesoblast Limited
MESO
$ 14.0 -3.06 % $ 16.9 B australiaAustralia
CorMedix CorMedix
CRMD
$ 5.37 -2.1 % $ 387 K usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
MannKind Corporation MannKind Corporation
MNKD
$ 4.22 0.84 % $ 1.29 B usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
MediciNova MediciNova
MNOV
$ 1.4 -4.76 % $ 68.7 M usaUSA
Merck & Co. Merck & Co.
MRK
$ 147.75 -0.68 % $ 370 B usaUSA
Moderna Moderna
MRNA
$ 250.79 -6.77 % $ 97.6 B usaUSA
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
Intellia Therapeutics Intellia Therapeutics
NTLA
$ 11.18 -7.72 % $ 1.21 B usaUSA
Novartis AG Novartis AG
NVS
$ 163.39 -0.18 % $ 317 B schweizSchweiz
Omeros Corporation Omeros Corporation
OMER
$ 17.3 -1.48 % $ 1.1 B usaUSA
Oramed Pharmaceuticals Oramed Pharmaceuticals
ORMP
$ 3.97 -0.75 % $ 164 M israelIsrael
Tyme Technologies Tyme Technologies
TYME
- 8.07 % $ 54 M usaUSA
Puma Biotechnology Puma Biotechnology
PBYI
$ 8.13 -3.22 % $ 407 M usaUSA
PDS Biotechnology Corporation PDS Biotechnology Corporation
PDSB
$ 1.02 -5.09 % $ 47.3 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 34.99 3.77 % $ 147 M usaUSA
Pfizer Pfizer
PFE
$ 29.34 0.36 % $ 167 B usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
PainReform Ltd. PainReform Ltd.
PRFX
$ 0.78 -4.24 % $ 505 K israelIsrael
Prothena Corporation plc Prothena Corporation plc
PRTA
$ 8.56 -2.51 % $ 461 M usaUSA
Arcus Biosciences Arcus Biosciences
RCUS
$ 18.66 -1.56 % $ 2 B usaUSA
Orgenesis Orgenesis
ORGS
- -33.86 % $ 61.2 M usaUSA
Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Limited
RDY
$ 14.9 -1.03 % $ 12.4 B indiaIndia
Regeneron Pharmaceuticals Regeneron Pharmaceuticals
REGN
$ 916.16 -0.41 % $ 95.8 B usaUSA
Replimune Group Replimune Group
REPL
$ 23.3 4.67 % $ 2.16 B usaUSA
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia